

When requesting Dysport® (abobotulinumtoxinA), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications or approved off-label compendial uses and meet the specific coverage guidelines and applicable safety criteria for the covered indications.

FDA-approved indications

- Dysport® (abobotulinumtoxinA) is indicated for the treatment of adults with cervical dystonia.
- Dysport® (abobotulinumtoxinA) is indicated for the treatment of upper limb spasticity in adult patients to decrease the severity of increased muscle tone in elbow flexors, wrist flexors, and finger flexors.
- Dysport® (abobotulinumtoxinA) is indicated for the treatment of lower limb spasticity in pediatric patients 2 years of age and older.

Approved Off-label Compendial use

- Blepharospasm
- Hemifacial spasm
- Achalasia

Coverage Guidelines

For all approved indications, the individual meets all of the following criteria:

- Does not have infection at the proposed injection site
- Does not have a known hypersensitivity to any botulinum toxin product or excipients
- Is not allergic to cow's milk protein

For Blepharospasm/Cervical dystonia/Upper limb spasticity/Hemifacial spasm:

- Is 18 years of age or older

For Lower limb spasticity:

- Is 2 years of age or older

For Achalasia:

- Is 18 years of age or older AND
- Had a poor response to pneumatic dilatation or is not a surgical candidate

Approval duration: 12 months

Additional Information for Prescribers

- The potency units of Dysport are not interchangeable with other preparations of botulinum toxin products
- The effects of Dysport and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life-threatening and there have been reports of death.
- Dysport contains human albumin. There is a risk for transmission of Creutzfeldt-Jakob disease (CJD). However, no cases of transmission of viral diseases or CJD have ever been identified for albumin

References

1. Dysport® prescribing information. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc: December 2016. https://www.dysport.com/pdfs/Dysport_Full_Prescribing_Information.pdf. Accessed February 16, 2017.
2. Klasco RK (Ed): DRUGDEX® System. Thomson Micromedex, Greenwood Village, CO. Accessed February 16, 2017. <http://www.micromedexsolutions.com>

CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2016 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein.